Standard Chartered Posts Stronger-Than-Expected 4Q Profit
By Sherry Qin
Standard Chartered PLC posted higher-than-expected fourth-quarter profit, supported by higher net interest income and sharply lower credit impairments.
The London-based lender, which earns most of its revenue in Asia, on Friday said its underlying pretax profit was $1.06 billion, beating the consensus of $957 million, according to estimates compiled by the company. The company reported pretax profit of $1.14 billion, sharply higher than $123 million in the year-earlier period.
The company recorded a $62 million credit impairment charge, down $232 million on quarter, due to charges in relation to the consumer, private and business banking segment, though this was partially offset by a net release from its corporate, commercial & institutional banking business.
The bank's underlying operating income rose to $4.02 billion, 7% higher than in the same period last year.
StanChart's underlying net interest income rose 6% to $2.39 billion, slightly lower than the estimate for $2.42 billion.
The lender said it would buy back up to $1 billion in shares starting immediately, which is expected to reduce it CET1 ratio by approximately 40 basis points.
The company expects its 2024 net interest income to be between $10 billion and $10.25 billion on a constant currency basis.
The bank also plans to return at least $5 billion to shareholders cumulatively over 2024 to 2026.
Write to Sherry Qin at sherry.qin@wsj.com
(END) Dow Jones Newswires
February 23, 2024 00:08 ET (05:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth